Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer

Cancer Treatment Reviews

Volumn 37, Issue 6, 2011, Pages 422-430

  Van de Ven, S ^a   Smit, V T H B M ^a   Dekker, T J A ^a   Nortier, J W R ^a   Kroep, J R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; Concordance; Estrogen receptor; Human Epidermal growth factor Receptor 2; Neoadjuvant chemotherapy; Progesterone receptor; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PREDNISOLONE; PROGESTERONE RECEPTOR; TRASTUZUMAB; VINCRISTINE;

BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; HUMAN; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOADJUVANT THERAPY; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 79960972539     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.11.006     Document Type: Review

References (65)

1. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996;14:2843-77.
2. Dowsett M., Dunbier A.K. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 2008, 14:8019-8026.
3. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
4. Gianni L., Baselga J., Eiermann W., et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005, 11:8715-8721.
5. Bear H.D., Anderson S., Smith R.E., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006, 24:2019-2027.
6. Colleoni M., Viale G., Zahrieh D., et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 2004, 10:6622-6628.
7. Ring A.E., Smith I.E., Ashley S., Fulford L.G., Lakhani S.R. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2004, 91:2012-2017.
8. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
9. Buzdar A.U., Ibrahim N.K., Francis D., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005, 23:3676-3685.
10. Gianni L., Eiermann W., Semiglazov V., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375:377-384.
11. Untch M., Von M.G. Recent advances in systemic therapy: advances in neoadjuvant (primary) systemic therapy with cytotoxic agents. Breast Cancer Res 2009, 11:203.
12. Untch M., Rezai M., Loibl S., et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010, 28:2024-2031.
13. Harris L., Fritsche H., Mennel R., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.
14. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
15. Arnedos M., Nerurkar A., Osin P., et al. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol 2009, 20:1948-1952.
16. MacGrogan G., Mauriac L., Durand M., et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 1996, 74:1458-1465.
17. Piper G.L., Patel N.A., Patel J.A., Malay M.B., Julian T.B. Neoadjuvant chemotherapy for locally advanced breast cancer results in alterations in preoperative tumor marker status. Am Surg 2004, 70:1103-1106.
18. Frassoldati A., Adami F., Banzi C., et al. Changes of biological features in breast cancer cells determined by primary chemotherapy. Breast Cancer Res Treat 1997, 44:185-192.
19. Makris A., Powles T.J., Allred D.C., et al. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study. Breast Cancer Res Treat 1999, 53:51-59.
20. Hawkins R.A., Tesdale A.L., Anderson E.D., et al. Does the oestrogen receptor concentration of a breast cancer change during systemic therapy?. Br J Cancer 1990, 61:877-880.
21. Lee S.H., Chung M.A., Quddus M.R., Steinhoff M.M., Cady B. The effect of neoadjuvant chemotherapy on estrogen and progesterone receptor expression and hormone receptor status in breast cancer. Am J Surg 2003, 186:348-350.
22. Arens N., Bleyl U., Hildenbrand R. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Arch 2005, 446:489-496.
23. Schneider J., Lucas R., Sanchez J., et al. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP. Anticancer Res 2000, 20:4373-4377.
24. Penault-Llorca F., Cayre A., Bouchet M.F., et al. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 2003, 22:1319-1325.
25. Taucher S., Rudas M., Gnant M., et al. Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer 2003, 10:91-98.
26. Kasami M., Uematsu T., Honda M., et al. Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy. Breast 2008, 17:523-527.
27. Burcombe R.J., Makris A., Richman P.I., et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 2005, 92:147-155.
28. Shet T., Agrawal A., Chinoy R., et al. Changes in the tumor grade and biological markers in locally advanced breast cancer after chemotherapy - implications for a pathologist. Breast J 2007, 13:457-464.
29. Hirata T., Shimizu C., Yonemori K., et al. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. Br J Cancer 2009, 101:1529-1536.
30. Neubauer H., Gall C., Vogel U., et al. Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res 2008, 28:1797-1804.
31. Jain V., Landry M., Levine E.A. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma. Am Surg 1996, 62:162-165.
32. Faneyte I.F., Schrama J.G., Peterse J.L., et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003, 88:406-412.
33. Bottini A., Berruti A., Bersiga A., et al. Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Res 1996, 16:3105-3110.
34. Varga Z., Caduff R., Pestalozzi B. Stability of the HER2 gene after primary chemotherapy in advanced breast cancer. Virchows Arch 2005, 446:136-141.
35. Miglietta L., Vanella P., Canobbio L., et al. Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index. Anticancer Res 2009, 29:1621-1625.
36. Adams A.L., Eltoum I., Krontiras H., Wang W., Chhieng D.C. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma. Breast J 2008, 14:141-146.
37. Tacca O., Penault-Llorca F., Abrial C., et al. Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 2007, 12:636-643.
38. Taucher S., Rudas M., Mader R.M., et al. Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer. Breast Cancer Res Treat 2003, 82:207-213.
39. Vincent-Salomon A., Jouve M., Genin P., et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 2002, 94:2169-2173.
40. Mittendorf E.A., Wu Y., Scaltriti M., et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009, 15:7381-7388.
41. Hurley J., Doliny P., Reis I., et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006, 24:1831-1838.
42. Harris L.N., You F., Schnitt S.J., et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007, 13:1198-1207.
43. Zidan A., Christie Brown J.S., Peston D., Shousha S. Oestrogen and progesterone receptor assessment in core biopsy specimens of breast carcinoma. J Clin Pathol 1997, 50:27-29.
44. Amir E., Clemons M. Should a biopsy be recommended to confirm metastatic disease in women with breast cancer?. Lancet Oncol 2009, 10:933-935.
45. Gown A.M. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008, 21(Suppl. 2):S8-S15.
46. Bueno-de-Mesquita J.M., Nuyten D.S., Wesseling J., et al. The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. Ann Oncol 2010, 21:40-47.
47. Viale G., Regan M.M., Maiorano E., et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007, 25:3846-3852.
48. Hammond M.E., Hayes D.F., Dowsett M., et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795.
49. Bines J., Oleske D.M., Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996, 14:1718-1729.
50. Rose D.P., Davis T.E. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res 1980, 40:4043-4047.
51. Rakha E.A., El-Sayed M.E., Green A.R., et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007, 25:4772-4778.
52. Dati C., Antoniotti S., Taverna D., Perroteau I., De B.M. Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 1990, 5:1001-1006.
53. Mathew J., Asgeirsson K.S., Jackson L.R., Cheung K.L., Robertson J.F. Neoadjuvant endocrine treatment in primary breast cancer - review of literature. Breast 2009, 18:339-344.
54. Miller W.R., Dixon J.M., Macfarlane L., Cameron D., Anderson T.J. Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer 2003, 39:462-468.
55. Ellis M.J., Coop A., Singh B., et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003, 63:6523-6531.
56. Zhu L., Chow L.W., Loo W.T., Guan X.Y., Toi M. Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial. Clin Cancer Res 2004, 10:4639-4644.
57. Simmons C., Miller N., Geddie W., et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol 2009, 20:1499-1504.
58. Liedtke C., Broglio K., Moulder S., et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009, 20:1953-1958.
59. Amir E, Clemons M, Freedman OC, et al. Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies. J Clin Oncol 2010 Annual Meeting Proceedings 2010;28:Abstract 1007.
60. Locatelli MA, Curigliano G, Fumagalli L, et al. Should liver metastases of breast cancer be biopsied to improve treatment choice? J Clin Oncol 2010 Annual Meeting Proceedings 2010;28:Abstract 1008.
61. Karlsson E, Lindstrom L, Wilking U, et al. Discordance in hormone receptor status in breast cancer during tumor progression. J Clin Oncol 2010 Annual Meeting Proceedings 2010;28:Abstract 1009.
62. Makris A., Powles T.J., Dowsett M., et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 1997, 3:593-600.
63. Rasbridge S.A., Gillett C.E., Seymour A.M., et al. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer 1994, 70:335-341.
64. Quddus R.M., Sung J.C., Zhang C., et al. HER-2/neu expression in locally advanced breast carcinomas: pre-and post-neoadjuvant chemotherapy. Breast Cancer 2005, 12:294-298.
65. Vargas-Roig L.M., Gago F.E., Tello O., Martin de Civetta M.T., Ciocca D.R. c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 1999, 84:129-134.